Skip to Content

Apresoline Side Effects

Generic Name: hydralazine

Note: This page contains information about the side effects of hydralazine. Some of the dosage forms included on this document may not apply to the brand name Apresoline.

For the Consumer

Applies to hydralazine: oral tablet

Other dosage forms:

In addition to its needed effects, some unwanted effects may be caused by hydralazine (the active ingredient contained in Apresoline). In the event that any of these side effects do occur, they may require medical attention.

Major Side Effects

You should check with your doctor immediately if any of these side effects occur when taking hydralazine:

More common:
  • Arm, back, or jaw pain
  • chest pain or discomfort
  • chest tightness or heaviness
  • fast, pounding, or irregular heartbeat or pulse
  • nausea
  • shortness of breath
  • sweating
Less common:
  • Black, tarry stools
  • blindness or vision changes
  • blisters on the skin
  • blurred vision
  • burning of the face or mouth
  • burning, crawling, itching, numbness, painful, prickling, "pins and needles", or tingling feelings
  • chills
  • clumsiness or unsteadiness
  • confusion
  • cough
  • difficult or labored breathing
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fever and sore throat
  • general feeling of discomfort or illness or weakness
  • joint pain
  • lower back or side pain
  • muscle pain
  • numbness, tingling, pain, or weakness in the hands or feet
  • painful or difficult urination
  • pale skin
  • shakiness in the legs, arms, hands, or feet
  • skin rash or itching
  • swelling of the feet or lower legs
  • swollen, painful, or tender lymph glands in the neck, armpit, or groin
  • tightness in the chest
  • trembling or shaking of the hands or feet
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • weakness in hands or feet
  • Dark urine
  • light-colored stools
  • upper right abdominal or stomach pain
  • yellow eyes and skin

If any of the following symptoms of overdose occur while taking hydralazine, get emergency help immediately:

Symptoms of overdose:
  • Feeling of warmth
  • headache
  • redness of the face, neck, arms, and occasionally, upper chest

Minor Side Effects

Some of the side effects that can occur with hydralazine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:
  • Diarrhea
  • loss of appetite
  • weight loss
Less common:
  • Constipation
  • difficulty with moving
  • dizziness
  • feeling anxious or depressed
  • muscle cramps, pain, or stiffness
  • pain in the joints
  • rash, hives, welts, or itching
  • stuffy nose
  • watery eyes

For Healthcare Professionals

Applies to hydralazine: compounding powder, injectable solution, oral tablet


Because up to 20% of patients who receive 400 mg per day or more develop a systemic lupus erythematosus syndrome, some experts recommend checking a patient's acetylator status before giving higher doses. Up to 70% of "resistant" patients are fast acetylators, in whom the dose can be relatively safely increased.

Data suggest that hydralazine (the active ingredient contained in Apresoline) lupus may represent a unique hypersensitivity reaction in which antibodies to native DNA occur. These antibodies are believed to account for the clinical similarities between hydralazine-induced lupus and systemic lupus erythematosus.[Ref]

Immunologic side effects including the development of a lupus-like syndrome has been reported. It is more likely in patients who receive 400 mg or more of hydralazine per day, in female patients, or in patients who are slow acetylators. Of patients who receive less than 200 mg or 400 mg or more per day of hydralazine, 40% and 50%, respectively, develop a positive ANA titer, and up to 6% and 14%, respectively, develop a lupus-like syndrome.

The lupus syndrome may present as arthralgias (most common), myalgias, lethargy, malaise, a typical erythematous rash, weight loss, or dyspnea, but may be found incidentally in asymptomatic patients by urinalysis (proteinuria, hematuria), blood chemistry (elevated ESR, antinuclear antibody), or chest X-ray (interstitial lung disease, rare). Hypocomplementemia is an extremely rare finding in hydralazine-induced lupus.

Alternative therapy is recommended for patients who develop the clinical appearance of a lupus syndrome, sustained rises in the antinuclear antibody titer, or the presence of LE cells. The syndrome is reversible, but may take months to years to resolve.[Ref]


Cardiovascular side effects are related to the vasodilatory properties of hydralazine (the active ingredient contained in Apresoline) Reflex tachycardia is commonly observed. Palpitations, flushing, edema, or chest pain have been reported in less than 5% of patients. The use of hydralazine in patients with severe chronic heart failure has been associated with ischemia, including episodes of myocardial infarction.

In patients with pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD), hydralazine may increase pulmonary artery hypertension, especially during periods of hypoxia. The use of hydralazine in these patients may, on rare occasions, result in profound hypotension, tachycardia, and even death.

Rare cases of bradycardia or cardiac tamponade (associated with hydralazine-induced lupus) have been reported. Hydralazine does not have a deleterious effect on the lipid profile, and, in fact, has been shown to decrease total and LDL cholesterol.[Ref]

Provocation of ischemia in patients with compromised left ventricular systolic dysfunction may be due to the inability of hydralazine to decrease preload, or left ventricular filling pressures.

The mechanism of increased pulmonary hypertension in patients with PH or COPD is a decrease of systemic vascular resistance accompanied by an increase in cardiac output without a fall in the pulmonary vascular resistance. In case reports and small series of patients, the use of hydralazine in such patients resulted in palpitations, chest tightness, unchanged pulmonary vascular resistance, increased pulmonary artery pressure, decreased systemic vascular resistance, and increased heart rate and cardiac output. For this reason, if hydralazine must be used, many experts recommend hemodynamic monitoring during hydralazine therapy in such patients.[Ref]

Nervous system

Nervous system side effects including peripheral neuropathy is dose-related and is more common in slow acetylators. The neuropathy usually first presents as paresthesias, numbness, and tingling in the extremities. It is probably the result of pyridoxine deficiency, perhaps because formation of a pyridoxal-hydralazine (the active ingredient contained in Apresoline) complex inactivates the coenzyme, and can, therefore, be treated by administration of pyridoxine. Headache or dizziness have been reported in approximately 5% of patients.[Ref]

A 61-year-old man with hypertension developed ataxia, numbness, and lower extremity weakness approximately six months after beginning hydralazine (up to 300 mg per day) and reserpine therapy. The neuropathy partially resolved after reduction of the hydralazine dosage to 60 mg daily. A complete evaluation revealed that this man was a slow acetylator of hydralazine.[Ref]


Respiratory side effects include nasal stuffiness, seen in approximately 3% of patients. A case of "hydralazine (the active ingredient contained in Apresoline) lung", associated with hydralazine-induced lupus has been reported.[Ref]

A 48-year-old woman with hypertension developed dyspnea, hemoptysis, pleurisy, proteinuria, and hematuria one year after beginning hydralazine (150 mg per day), polythiazide, and atenolol therapy. Other associated findings included an elevated ESR, antinuclear factor, anti-DNA titer, a positive LE test, and radiographic findings of diffuse interstitial lung disease. Two weeks after stopping hydralazine, the signs and symptoms of lupus with pulmonary involvement disappeared.

At least one fatal case of hydralazine-induced lupus pneumonitis has been reported. The patient had been taking hydralazine for more than a year prior to developing symptoms.

A rare case of hydralazine-induced lupus presenting as laryngeal edema and right vocal fold paralysis has been reported. The patient had been taking hydralazine 50 mg three times daily and exhibited hoarseness of voice and inspiratory stridor. Discontinuation of hydralazine resulted in reversal of paralysis.[Ref]


A 71-year-old man with hypertension developed anorexia, weight loss, petechiae, and a microcytic anemia during therapy with hydralazine (the active ingredient contained in Apresoline) and oxprenolol. Evaluation for iron deficiency, hemolysis, or marrow depression was negative. The patient was found to have fecal blood loss, anti-DNA antibodies, decreased complement levels, a normal upper GI series, and biopsy-proven vasculitis. The syndrome resolved within two weeks after discontinuation of hydralazine.[Ref]

Hematologic abnormalities have been associated with the hydralazine-induced lupus-like syndrome. Anemia may be caused by one of at least four hydralazine-associated problems; hemolysis, the formation of a circulating anticoagulant, thrombocytopenia, and vasculitis. Rare cases of leukopenia and agranulocytosis have been reported.[Ref]


Renal side effects are common in idiopathic systemic lupus erythematosus; however, immune complex glomerulonephritis is rare in drug-induced lupus. Rare cases of rapidly progressive and focal glomerulonephritis associated with the hydralazine-induced lupus syndrome are often accompanied by anemia, a positive anti-DNA antibody titer, and a positive ANA titer.[Ref]

In one study, rapidly progressive glomerulonephritis (RPGN) is described in 4 of 444 patients, all of whom were men who were treated for 5 to 11 years with daily doses of 100 to 250 mg. In three of the four cases, biopsy revealed a focal and segmental glomerular necrosis with crescents and positive immunofluorescence. The antinuclear antibody titer became positive in three. Renal function improved in all but one after the withdrawal of hydralazine and institution of corticosteroid therapy. A number of other cases of RPGN are reported. It appears to be far more common in patients who are slow acetylators.[Ref]


A 65-year-old man with ischemic cardiomyopathy developed a pruritic, erythematous, generalized rash within two months after beginning hydralazine (the active ingredient contained in Apresoline) (200 mg per day) therapy. There were no clinical or laboratory signs of lupus. The rash persisted upon gradual withdrawal of the patient's other medications, but cleared only after discontinuation of hydralazine. Rechallenge resulted in a recurrent pruritic rash.[Ref]

Dermatologic manifestations of the hydralazine-induced lupus-like syndrome include cutaneous vasculitis. A generalized, pruritic rash without evidence of lupus has been associated with hydralazine. Rare cases of Sweet's syndrome (neutrophilic dermatosis) have been associated with hydralazine.[Ref]


A 59-year-old woman with hypertension and cholecystic gallbladder disease developed abdominal pain, nausea, vomiting, painful hepatomegaly, elevated serum transaminases, direct hyperbilirubinemia, and liver biopsy findings of subacute hepatitis (with bridging necrosis) within two days after hydralazine (the active ingredient contained in Apresoline) was added to her medical regimen. The signs and symptoms of hepatitis resolved after all medications were withheld, but returned upon rechallenge with hydralazine.[Ref]

Hepatic reactions are rare. Less than ten cases of hepatitis have been reported, many of which were believed to be due to hypersensitivity. Histological findings include hepatocellular, cholestatic, mixed hepatocellular-cholestatic, and granulomatous patterns.[Ref]


A 44-year-old woman with hypertension and acute sinusitis developed acute renal failure, edema, and a generalized maculopapular erythematous rash during therapy with ampicillin (for sinusitis), hydrochlorothiazide, and hydralazine (the active ingredient contained in Apresoline) A complete evaluation revealed bilateral hydronephrosis and hydroureters secondary to ureteral obstruction due to retroperitoneal fibrosis. Renal function returned to baseline after oral prednisone therapy. It is unclear whether this problem was due to one or more of her medications.[Ref]

Hypersensitivity reactions are rare. Many of the rare cases of hepatitis are believed to be due to hypersensitivity. A case of retroperitoneal fibrosis and of occupational asthma are believed to be due to hypersensitivity.[Ref]


Genitourinary side effects including impotence in male patients have been reported rarely.[Ref]

At least two cases of male impotence associated with hydralazine are reported. The mechanism is unclear. There was no evidence of a neuropathy in either case.[Ref]


Musculoskeletal manifestations of hydralazine-induced lupus include joint pain, arthralgias, and myalgias. Arthritis in the hands and wrists is a particularly common clinical manifestation.[Ref]


The incidence of hydralazine-induced systemic lupus erythematosus (SLE) is estimated at 5.4% for patients receiving 100 mg daily, 10.4% for those receiving 200 mg daily, and 10% to 20% for those receiving 400 mg or more daily. It should be noted that hydralazine-induced SLE has occurred at doses as low as 50 mg daily. Risk factors associated with development of hydralazine-induced SLE include slow acetylator status, HLA-DRw4 phenotype, female gender, high daily dose, therapy longer than 3 months, and a family history of autoimmune disease. Black patients appear to develop hydralazine-induced SLE less frequently than other populations. Musculoskeletal symptoms appear to be the most common clinical manifestation of hydralazine-induced SLE; however, it appears that any organ system can be involved. Laboratory findings that may aid in the diagnosis of hydralazine-induced SLE include antinuclear antibody (ANA), lupus erythematosus cells, rheumatoid factor, and antihistone antibodies.[Ref]


1. Pirmohamed M "Hydralazine-induced lupus: yet another autoantibody! triplex-DNA stabilization by hydralazine and the presence of anti-(triplex DNA) antibodies in patients treated with hydralazine - comment." Hum Exp Toxicol 15 (1996): 361-2

2. Darwaza A, Lamey P-J, Connell JM "Hydrallazine-induced Sjogren's syndrome." Int J Oral Maxillofac Surg 17 (1988): 92-3

3. Freestone S, Ramsay LE "Transient monoclonal gammopathy in hydralazine-induced lupus erythematosus." Br Med J 285 (1982): 1536-7

4. Sequeira W, Polisky RB, Alrenga DP "Neutrophilic dermatosis (Sweet's Syndrome)." Am J Med 81 (1986): 558-60

5. Bernstein RM, Egerton-Vernon J, Webster J "Hydrallazine-induced cutaneous vasculitis." Br Med J 280 (1980): 156-7

6. Naparstek Y, Kopolovic J, Tur-Kaspa R, Rubinger D "Focal glumerulonephritis in the course of hydralazine-induced lupus syndrome." Arthritis Rheum 27 (1984): 822-5

7. Sturman SG, Kumararatne D, Beevers DG "Fatal hydralazine-induced systemic lupus erythematosus." Lancet 12/03/88 (1988): 1304

8. Kincaid-Smith P, Whitworth JA "Hydralazine-associated glomerulonephritis." Lancet 2 (1983): 348

9. Bass BH "Hydralazine lung." Thorax 36 (1981): 695-6

10. Weinstein J "Hypocomplementemia in hydralazine-associated systemic lupus erythematosus." Am J Med 65 (1978): 553-6

11. Cameron HA, Ramsay LE "The lupus syndrome induced by hydralazine: a common complication with low dose treatment." Br Med J 289 (1984): 410-12

12. Fleming MG, Bergfeld WF, Tomecki KJ, et al "Bullous systemic lupus erythematosus." Int J Dermatol 28 (1989): 321-6

13. Shapiro KS, Pinn VW, Harrington JT, Levey AS "Immune complex glomerulonephritis in hydralazine-induced SLE." Am J Kidney Dis 3 (1984): 270-4

14. Finlay AY, Statham B, Knight AG "Hydrallazine-induced necrotising vasculitis." Br Med J 282 (1981): 1703-4

15. Carey RM, Coleman M, Feder A "Pericardial tamponade: a major presenting manifestation of hydralazine-induced lupus syndrome." Am J Med 54 (1973): 84-7

16. Bjorck S, Svalander C, Westberg G "Hydralazine-associated glomerulonephritis." Acta Med Scand 218 (1985): 261-9

17. Hahn BH, Sharp GC, Irvin WS, et al "Immune responses to hydralazine and nuclear antigens in hydralazine-induced lupus erythematosus." Ann Intern Med 76 (1972): 365-74

18. Ludmerer KM, Kissane JM "Clinopathologic conference: renal failure, dyspnea and anemia in a 57 year old woman." Am J Med 71 (1981): 876-86

19. Ramsey-Goldman R, Franz T, Solano FX, Medsger TA "Hydralazine induced lupus and sweet's syndrome: report and review of the literature." J Rheumatol 17 (1990): 682-4

20. Koch-Weser J "Hydralazine." N Engl J Med 295 (1976): 320-3

21. Lunde PK, Frislid K, Hansteen V "Disease and acetylation polymorphism." Clin Pharmacokinet 2 (1977): 182-97

22. Blumenkrantz N, Christiansen AH, Ullman S, Asboe-Hansen G "Hydralazine-induced lupoid syndrome." Acta Med Scand 195 (1974): 443-9

23. Innes A, Rennie JA, Cato GR "Drug-induced lupus caused by very-low-dose hydralazine." Br J Rheumatol 25 (1986): 225-31

24. Perry HM "Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis." Am J Med 54 (1973): 58-72

25. Widgren B, Berglund G, Andersson OK "Side-effects in long-term treatment with hydralazine." Acta Med Scand 714 (1986): 193-6

26. Brooks AP, Paulley JW "Cutaneous manifestations of hydrallazine toxicity." Br Med J 02/16/80 (1980): 482

27. Peacock A, Weatherall D "Hydralazine-induced necrotising vasculitis." Br Med J 282 (1981): 1121-2

28. Timbrell JA, Facchini V, Harland SJ, Mansilla-Tinoco R "Hydralazine-induced lupus: is there a toxic metabolic pathway?" Eur J Clin Pharmacol 27 (1984): 555-9

29. Cush JJ, Goldings EA "Southwestern internal medicine conference: drug-induced lupus: clinical spectrum and pathogenesis." Am J Med Sci 290 (1985): 36-45

30. Ihle BU, Whitworth JA, Dowling JP, Kincaid-Smith P "Hydralazine and lupus nephritis." Clin Nephrol 22 (1984): 230-8

31. Packer M, Greenberg B, Massie B, Dash H "Deleterious effects of hydralazine in patients with pulmonary hypertension." N Engl J Med 306 (1982): 1326-31

32. Danielson M, Kjellberg J, Ohman P, Wernersson B "Evaluation of once daily hydralazine in inadequately controlled hypertension." Acta Med Scand 214 (1983): 373-80

33. Hammond TG, Mosesson MW "Fatal small-bowel necrosis and pulmonary hypertension in sickle cell disease." Arch Intern Med 149 (1989): 447-8

34. Miller AJ, Abrams DL, Kaplan BM "Persistent reversal of severe systemic hypertension after prolonged toxic reaction to hydralazine." Cardiology 60 (1975): 251-6

35. Wehner RJ, Romanauskas VS "An adverse reaction with hydralazine: a case study." AANA J June (1981): 274-5

36. Lodeiro JG, Feinstein SJ, Lodeiro SB "Fetal premature atrial contractions associated with hydralazine." Am J Obstet Gynecol 160 (1989): 105-7

37. Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995): 217-20

38. Keller CA, Shepard JW, Chun DS, et al "Effects of hydralazine on hemodynamics, ventilation, and gas exchange in patients with chronic obstructive pulmonary disease and pulmonary hypertension." Am Rev Respir Dis 129 (1984): 606-11

39. Tuxen DV, Powles AC, Mathur PN, et al "Detrimental effects of hydralazine in patients with chronic air-flow obstruction and pulmonary hypertension." Am Rev Respir Dis 129 (1984): 388-95

40. Laslett LJ, DeMaria AN, Amsterdam EA, Mason DT "Hydralazine-induced tachycardia and sodium retention in heart failure: hemodynamic and symptomatic correlation by prazosin therapy." Arch Intern Med 138 (1978): 819-20

41. Lins L-E, Berglund J, Eliasson K, Wernersson B "Efficacy and tolerability of hydralazine, in conventional and slow-release preparations, during long-term treatment of primary hypertension." Clin Ther 5 (1983): 251-9

42. Kronzon I, Cohen M, Winer HE "Adverse effect of hydralazine in patients with primary pulmonary hypertension." JAMA 247 (1982): 3112-4

43. Packer M, Meller J, Medina N, et al "Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure." Am J Cardiol 48 (1981): 939-46

44. Fagan TC, Sternleib C, Vlachakis N, et al "Efficacy and safety comparison of nitrendipine and hydralazine as antihypertensive monotherapy." J Cardiovasc Pharmacol 6 (1984): s1109-13

45. Williams LL, Lopez LM, Thorman AD, et al "Plasma lipid profiles and antihypertensive agents: effects of lisinopril, enalapril, nitrendipine, hydralazine, and hydrochlorothiazide." Drug Intell Clin Pharm 22 (1988): 546-50

46. Aylward PE, Tonkin AM "Cardiac tamponade in hydrallazine-induced systemic lupus erythematosus." Aust N Z J Med 12 (1982): 546

47. Tsujimoto G, Horai Y, Ishizaki T, Itoh K "Hydralazine-induced peripheral neuropathy seen in a Japanese slow acetylator patient." Br J Clin Pharmacol 11 (1981): 622-5

48. Hari CK, Raza SA, Clayton MI "Hydralazine-induced lupus and vocal fold paralysis." J Laryngol Otol 112 (1998): 875-7

49. Perrin B, Malo J-L, Cartier A, et al "Occupational asthma in a pharmaceutical worker exposed to hydralazine." Thorax 45 (1990): 980-1

50. Birnbaum B, Sidhu GS, Smith RL, Pillinger MH, Tagoe CE "Fulminating hydralazine-induced lupus pneumonitis." Arthritis Rheum 55 (2006): 501-506

51. Singh S "Hydralazine-induced lupus." South Med J 99 (2006): 6-7

52. Finks SW, Finks AL, Self TH "Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure." South Med J 99 (2006): 18-22

53. Macleod WN "Anaemia in the hydrallazine-induced lupus syndrome." Scott Med J 28 (1983): 181-2

54. Widerlov E, Karlman I, Storsater J "Hydralazine-induced neonatal thrombocytopenia." N Engl J Med 303 (1980): 1235

55. Orenstein AA, Yakulis V, Eipe J, Costea N "Immune hemolysis due to hydralazine." Ann Intern Med 86 (1977): 450-1

56. Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995): 247-8

57. Gilmour E, Chalmers RJG, Rowlands DJ "Drug-induced sweet's syndrome (acute febrile neutrophilic dermatosis) associated with hydralazine." Br J Dermatol 133 (1995): 490-1

58. Schapel GJ "Skin rash and hydralazine." Med J Aust 141 (1984): 765-6

59. Young EJ, Fainstein V, Musher DM "Drug-induced fever: cases seen in the evaluation of unexplained fever in a general hospital population." Rev Infect Dis 4 (1982): 69-77

60. Stewart GW, Peart WS, Boylston AW "Obstructive jaundice, pancytopenia and hydralazine." Lancet 05/30/81 (1981): 1207

61. Itoh S, Yamaba Y, Ichinoe A, Tsukada Y "Hydralazine-induced liver injury." Dig Dis Sci 25 (1980): 884-7

62. Myers JL, Augur NA "Hydralazine-induced cholangitis." Gastroenterology 87 (1984): 1185-8

63. Bartoli E, Massarelli G, Solinas A, et al "Acute hepatitis with bridging necrosis due to hydralazine intake." Arch Intern Med 139 (1979): 698-9

64. Podevin P, Biour M "Drug-induced ''allergic hepatitis''." Clin Rev Allergy Immunol 13 (1995): 223-44

65. Forster HS "Hepatitis from hydralazine." N Engl J Med 303 (1980): 1362

66. Barnett DB, Hudson SA, Golightly PW "Hydralazine-induced hepatitis." Br Med J 05/10/80 (1980): 1165-6

67. Rice D, Burdick CO "Granulomatous hepatitis from hydralazine therapy." Arch Intern Med 143 (1983): 1077

68. Jori GP, Peschle C "Hydralazine disease associated with transient granulomas in the liver." Gastroenterology 64 (1973): 1163-7

69. Waters VV "Hydralazine, hydrochlorothiazide and ampicillin associated with retroperitoneal fibrosis: case report." J Urol 141 (1989): 936-7

70. Marinella MA, Billi JE "Lisinopril therapy associated with acute pancreatitis." West J Med 163 (1995): 77-8

71. Keidan H "Impotence during antihypertensive treatment." Can Med Assoc J 114 (1976): 874

Not all side effects for Apresoline may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.